Clinical Trials Logo

Clinical Trial Summary

This is a multi-center, non-randomized and open-label phase I/IIa clinical study to evaluate the safety, tolerability, and efficacy of ICP-490 in patients with relapsed and/or refractory multiple myeloma.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05719701
Study type Interventional
Source Beijing InnoCare Pharma Tech Co., Ltd.
Contact April Huang
Phone 010-66609723
Email April.huang@innocarepharma.com
Status Recruiting
Phase Phase 1/Phase 2
Start date March 29, 2023
Completion date December 30, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT03140943 - Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Phase 2
Recruiting NCT05066022 - A Study to Access the Safety and Efficacy of CT0590 in Patients With Relapsed and/or Refractory Multiple Myeloma N/A
Recruiting NCT06182696 - OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM Phase 1/Phase 2
Recruiting NCT03715478 - Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex Phase 1/Phase 2
Completed NCT02917941 - A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma Phase 2
Not yet recruiting NCT03903406 - Quality of Life, Symptoms and Treatment Satisfaction in Adult Patients With Relapsed and/or Refractory Multiple Myeloma, Receiving Ixazomib (Ninlaro®) in Combination With Lenalidomide and Dexamethasone in a Real World Setting: Pilot Study
Completed NCT03242460 - The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM) Phase 2
Terminated NCT03836053 - Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma Phase 1
Recruiting NCT05297240 - Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.
Terminated NCT04272775 - A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) Phase 1
Not yet recruiting NCT06351644 - ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Phase 1/Phase 2
Withdrawn NCT04392648 - A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Phase 1
Active, not recruiting NCT01632150 - Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Phase 2
Completed NCT02831686 - A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma Phase 1
Recruiting NCT06153251 - A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma Phase 1
Completed NCT00882063 - Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple Myeloma Phase 1/Phase 2
Terminated NCT04017130 - A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT03416374 - A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy Phase 4
Recruiting NCT05486975 - This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma. Early Phase 1
Completed NCT03170882 - A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma Phase 2